

the IPER, as applicable, will also include documents which would be relevant if the application were to be redated (see GL/PCT-EPO B-III, 2.3.3).

A review of the decision by the RO can only take place in the regional phase (Rule 82ter.1(b)).

After entry into the regional phase before the EPO (Euro-PCT phase) the applicant can withdraw the later filed parts, in order to avoid the redating of the application. In this case, it should be noted that amendments which are acceptable under the less strict criterion of Art. 123(2) EPC can always be filed during the Euro-PCT phase.

### **2.2.3 Sequence listings filed after the date of filing**

Any sequence listing not contained in the international application as filed will – if not allowable as an amendment under Article 34 – not form part of the international application.

Rule 13ter.1(c)

See GL/PCT-EPO B-VIII, 3.2, for the effect on the search and GL/PCT-EPO B-XI, 7, for the effect on the WO-ISA. For the effect on examination in Chapter II, see GL/PCT-EPO C-VIII, 2.1.

### **2.2.4 Priority documents**

It is not permissible to add to an international application matter present only in the priority document for that application, unless this is done under the provisions of Rule 20.6 (GL/PCT-EPO H-II, 2.2.2). For correction of errors, see GL/PCT-EPO H-IV.

### **2.2.5 Citation of prior art in the description after the filing date**

The examiner should apply the guidelines of section H-IV, 2.2.6, in the Guidelines for Examination in the EPO *mutatis mutandis*.

GL/ISPE 20.10

### **2.2.6 Clarification of inconsistencies**

The examiner should apply the guidelines of section H-IV, 2.2.7, in the Guidelines for Examination in the EPO *mutatis mutandis*.

GL/ISPE 20.10

### **2.2.7 Trademarks**

The examiner should apply the guidelines of section H-IV, 2.2.8, in the Guidelines for Examination in the EPO *mutatis mutandis*.

## **2.3 Assessment of "added subject-matter" – examples**

The examiner should apply the guidelines of section H-IV, 2.4, in the Guidelines for Examination in the EPO *mutatis mutandis*.

GL/ISPE 20.13

## **3. Compliance of amendments with other PCT requirements**

The examiner should apply the guidelines of section H-IV, 4.2, in the Guidelines for Examination in the EPO *mutatis mutandis*.

GL/ISPE 20.09